Sisaf
Latest round
- Series B
Last raised
- Jul 2019
Total raised
- $22M
Investors
- 5
About Sisaf
Founded in 2006 and headquartered in Guildford, UK, Sisaf Limited specializes in RNA therapeutics and has completed a total of 4 deals. The founder's history is not publicly detailed, and no subsidiaries or parent companies are mentioned.SiSaf Ltd specializes in innovative RNA delivery and therapeutics, primarily utilizing its proprietary Bio-Courier® technology, which integrates bioabsorbable silicon with organic materials. This technology enhances the delivery of nucleic acids across a range of therapeutic applications, effectively addressing shortcomings associated with conventional delivery methods such as lipid nanoparticles. SiSaf's primary focus areas include the development of RNA therapeutics for solid tumors, such as pancreatic ductal adenocarcinoma, metastatic cancers, and rare skeletal disorders like autosomal dominant Osteopetrosis Type II.SiSaf Ltd generates revenue through strategic partnerships and licensing agreements, particularly in the biopharmaceutical sector. The company engages in business-to-business transactions, collaborating with research institutions and pharmaceutical companies to develop and commercialize RNA-based therapies. Typical agreements may involve upfront payments, milestone payments linked to specific development targets, and royalties based on product sales once commercialized. The flagship Bio-Courier® technology serves as a cornerstone of its offerings, enhancing the therapeutic delivery of RNA molecules and aiming to penetrate various markets, including oncology and rare genetic disorders. The company aims to expand its product offerings and is currently designing new RNA therapeutics targeting solid tumors and rare genetic disorders, with potential launches expected in the next few years. Additionally, Sisaf is exploring opportunities to penetrate new geographic markets, specifically targeting regions in Asia and the Americas by 2025, to broaden its reach and impact in the biopharmaceutical industry.
Who invested in Sisaf
5 investors across 3 rounds
See all investors in Sisaf
Sign up free to see every VC on the cap table, the rounds they joined, and how much each round raised.
Questions about Sisaf
Who invested in Sisaf?
Sisaf has 5 investors on record across 3 venture rounds. Sign up free to see every VC on the cap table and the rounds they joined.
How much funding has Sisaf raised?
Sisaf has raised 3 venture rounds. Sign up free to see how much each round raised and the total.
When did Sisaf last raise money?
Sisaf's most recent round on record is a Series B, in Jul 2019.
What does Sisaf do?
Founded in 2006 and headquartered in Guildford, UK, Sisaf Limited specializes in RNA therapeutics and has completed a total of 4 deals.
Where is Sisaf headquartered?
Sisaf is headquartered in Guildford, UK.
Which VCs invest in companies like Sisaf?
Among active investors with capital left to deploy, Index Ventures, Forbion, European Investment Bank and Generation Investment Management back biotechnology companies at Sisaf's stage. Their profiles are linked below.
VCs backing biotechnology startups at Series B
Raising like Sisaf? Find the right VCs.
Capital Atlas matches your startup to active investors by stage, sector and region.